Full-Time
Scientific Director
Immune Diseases and Inflammation, In Vitro Pharmacology
Posted on 8/21/2026
WuXi AppTec
1,001-5,000 employees
Global contract research, development, manufacturing organization
No salary listed
United States
Remote
PhD
 Biology & Biotech (1) |
|---|
Get referred to WuXi AppTec
See people who can refer or advise you
- A Ph.D. in Biology, Pharmacology, or a related discipline, with a focus on immune diseases, especially autoimmune diseases.
- At least 8 years of experience in a strategic or leadership role within a contract research organization, biotechnology, or pharmaceutical setting.
- A strong scientific background demonstrated through a publication record in immune diseases, particularly autoimmune diseases.
- Hands-on experience with in vitro assay development, validation, and data analysis in immune or inflammatory drug discovery.
- Excellent written and oral communication skills in English, with the ability to engage effectively with clients and internal teams.
- The ability to work collaboratively in a matrixed environment and support business growth through scientific excellence.
- Develop and implement strategic plans to advance the in vitro immune disease assay and screening platform.
- Build and maintain strong client relationships, understand clients' scientific needs, and ensure high levels of customer satisfaction.
- Provide scientific leadership and guidance across projects, fostering innovation and ensuring scientific rigor.
- Monitor emerging scientific trends and breakthroughs in immune diseases, and recommend new capabilities or approaches.
- Collaborate with cross-functional teams and senior management to align strategies and create synergies across the organization.
- Support business development and marketing efforts through scientific presentations, client meetings, and contributions to proposals and marketing materials.
- Ensure clear and effective communication of program updates, data, and scientific insights to clients and internal stakeholders.
- Experience in client-facing roles or scientific consultancy.
What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Huangpu, China
Founded
2000
Get referred to WuXi AppTec
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 revenue rose 38.9% to RMB 28.90 billion, with backlog reaching RMB 66.43 billion.
- Middletown, Delaware opens in Q4 2026, expanding U.S. manufacturing capacity before 2027 demand.
- Capex increased to RMB 7.5-8.5 billion, funding global expansion across Asia, Europe, and America.
What critics are saying
- The Pentagon's June 2026 1260H designation threatens U.S. customer access and procurement relationships.
- DoD's July 2026 court filing strengthens the military-company case, prolonging legal and commercial uncertainty.
- Chinese geopolitical exposure creates an existential off-ramp risk if U.S. restrictions widen further.
What makes WuXi AppTec unique
- WuXi AppTec's integrated CRDMO platform spans discovery, development, and manufacturing globally.
- Its TIDES platform is scaling peptide and oligonucleotide capacity across China, Singapore, and Delaware.
- Thirty years of customer audits and 20 ISO/IEC 27001 sites support regulated pharmaceutical outsourcing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%WuXi AppTec reported strong first-half 2026 results and raised its full-year guidance. The Chinese pharmaceutical contract research, development, and manufacturing organisation posted H1 revenue of RMB 28.90 billion, up 38.9% year-on-year, with continuing operations revenue rising 48.0%. Adjusted non-IFRS net profit increased 83.2% to RMB 11.57 billion, whilst the gross profit margin expanded 9.4 percentage points to 53.9%. The company's backlog for continuing operations grew 25.2% to RMB 66.43 billion as of 30 June 2026. WuXi AppTec raised its 2026 total revenue target to RMB 58.5–60.5 billion, up from RMB 51.3–53.0 billion previously. The firm also increased its capital expenditure guidance to RMB 7.5–8.5 billion to support accelerated global capacity expansion. The company addressed its inclusion on the US Department of Defence's 1260H list, calling it erroneous and confirming legal action to protect stakeholder interests.
WuXi AppTec DMPK has launched an automated compound management platform serving thousands of pharmaceutical and biotechnology companies worldwide, with storage capacity exceeding one million compounds. The system provides full lifecycle management through digital operations, featuring automated robotic retrieval, real-time weighing data integration with high-precision balances, and automated preparation via Hamilton systems. The platform addresses three major challenges in drug metabolism and pharmacokinetics research: diverse container types, large compound libraries, and strict storage requirements. Key capabilities include real-time logistics tracking, image recognition-based automated picking, and high-density mobile storage delivering approximately fourfold capacity versus fixed-cabinet layouts. The system maintains tamper-proof audit logs and role-based access control whilst integrating with the Mosaic Compound Management System. WuXi AppTec DMPK offers flexible managed services covering sample receipt, secure storage, distribution, and disposal, aiming to reduce operational costs and accelerate research timelines.
WuXi AppTec is expanding its global manufacturing capabilities for emerging drug modalities including peptides, oligonucleotides and targeted protein degraders, according to Pharma Manufacturing. The company's WuXi TIDES platform, focused on oligonucleotides and peptides, is projected to achieve approximately 40% year-on-year revenue growth in 2026. The company's solid-phase peptide synthesis reactor volume exceeded 100,000 litres at end-2025 and is expected to reach 130,000 litres by end-2026. New production facilities are under construction in Taixing, China, scheduled for 2027 operation, and Singapore, planned for 2028. WuXi AppTec is investing in process technologies combining solid-phase and liquid-phase synthesis to improve scalability for complex molecules. The company is also developing integrated approaches for antibody-drug conjugates and targeted protein degraders, incorporating earlier-stage chemistry and biology integration.
WuXi AppTec has been added to the Pentagon's list of "Chinese military companies", escalating tensions between the pharmaceutical manufacturer and the US. The Department of Defence updated its Section 1260H list on 8 June, adding WuXi alongside other Chinese firms including BYD and Comac. The DoD claims WuXi has links to China's State Administration for Science, Technology and Industry for National Defence and the People's Liberation Army. WuXi strongly denied the designation, calling it "clearly a mistake" and stating it is not owned, controlled or affiliated with any Chinese military or government entity. The contract research and manufacturing organisation, which operates in over 30 countries, reported revenues of $1.83 billion in Q1 2026, up 39.4% year-over-year. WuXi was previously removed from the BIOSECURE Act in October 2025.
WuXi AppTec is accelerating global manufacturing expansion across the United States, Europe and Asia, increasing capital expenditures by at least 17% this year to between RMB 6.5 billion and RMB 7.5 billion. The pharmaceutical contract research, development and manufacturing organisation is responding to growing customer demand, particularly for peptides and oligonucleotides. The company's new Middletown, Delaware facility will begin oral solid dosage manufacturing in Q4 2026, becoming its largest US site at 1.74 million square feet. In Europe, WuXi is expanding its Couvert, Switzerland site, whilst a Singapore facility is expected to begin Phase I operations in 2027. WuXi AppTec's small molecule pipeline reached 3,550 molecules by end-March 2026. Its TIDES business is projected to grow approximately 40% year-over-year.